US › Healthcare

Avalo Therapeutics Inc (AVTX)

US · Healthcare · Biotechnology

$18.53+2.66%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-19.6M

Profit YoY

-49.3%

EPS

$-0.98

EPS estimate

$-1.03

EPS came in at -0.98 against a street estimate of -1.03 — a beat of 4.9%.

Key statistics

Market cap

$965.5M

Forward P/E

0.0

P/B

14.13

Book value

$2.77

EPS (TTM)

$-5.57

52-week high

$24.27

52-week low

$8.00

50-day MA

$17.01

200-day MA

$16.52

Beta

0.79

Analyst view

Analysts rate Avalo Therapeutics Inc a strong buy (7 buy, 1 hold, 0 sell out of 8) with an average price target of $44.69.

Shareholding

Insiders

1.72%

Institutions

76.36%

Largest institutional holders

Fund	Stake
FMR Inc	5.44%
T. Rowe Price Investment Management,Inc.	4.09%
Caligan Partners LP	3.09%
Bvf Inc	3.09%
venBio Select Advisor LLC	2.67%
Affinity Asset Advisors, LLC	2.53%
Nantahala Capital Management, LLC	2.33%
UBS Group AG	2.16%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Avalo Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.